Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
A New Leaf for Vascular Growth Factor—Supports Dendritic Trees
18 July 2011. Neurons and synapses follow a “use it or lose it” paradigm—regular nerve firing promotes survival as well as maintenance of the dendrite tree. A paper in last week's Neuron links neural activity and dendritic branching to memory, via nuclear calcium and vascular endothelial growth factor D (VEGF-D). Without this signaling, dendrites cannot maintain their full complexity, limiting learning and memory. The work reveals a role for VEGF-D above and beyond support for blood vessels, and suggests that therapeutics targeting the factor, such as those used in cancer treatment, could have unwanted side effects on cognition. First author Daniela Mauceri and senior author Hilmar Bading of the University of Heidelberg, Germany, led the study.

The evidence for VEGF-D’s involvement in arborization and memory is “very compelling,” wrote Albert La Spada of the University of California in San Diego in an e-mail to ARF.

When a nerve receives and transmits an action potential, it causes calcium to enter the nucleus, where the anion partners with calmodulin to activate gene transcription (reviewed in Greer and Greenberg, 2008). Bading’s team previously found that neuron survival depends on this nuclear calcium signaling (Lau and Bading, 2009; Papadia et al., 2005). In the current work, the scientists turned their attention to the role of calcium signaling in dendrite morphology.

When Mauceri expressed a calmodulin-blocking peptide, M13, in primary hippocampal neuron cultures, they observed shorter, less complex dendrite arbors with fewer, skimpier spines than in cells with normal calcium activity. The scientists went back to a transcriptome analysis they had already performed (Zhang et al., 2009) to identify VEGF-D as a candidate mediator of the arborization phenotype. VEGF-D turns on in response to both nuclear calcium and calcium/calmodulin-dependent protein kinase IV (CaMKIV), which is involved in dendrite and spine morphology (Chow et al., 2005).

To confirm the vascular factor’s role in arborization, Mauceri added recombinant VEGF-D protein to the cultured neurons. It rescued the dendrite phenotype caused by M13 treatment. She also used RNA interference to block VEGF-D production in neurons with normal calcium activity. The dendrites lost complexity just as if calcium were blocked. Unlike M13, neither VEGF-D nor its interfering RNA affected dendritic spines, suggesting that some other pathway involving calcium controls their density and morphology.

Next, the researchers took their work in vivo. Mauceri injected the hippocampi of adult mice with an adeno-associated virus carrying the anti-VEGF-D RNA, selectively knocking out the gene. The neural morphology mirrored that seen in vitro: short dendrites with less branching than normal.

One might think that, once dendrites set up their branches, they stay the same, Bading said. But the evidence says otherwise. “It looks like you really need something to maintain this arborization,” he said.

That maintenance is key to learning and memory, the researchers discovered. They tested mice that lacked hippocampal VEGF-D, and mice injected with a scrambled RNA interference sequence, in both the Morris water maze and a contextual fear-conditioning task. The VEGF knockdowns had trouble recalling the location of a hidden platform in the former, and were less likely to remember which chamber led to an unpleasant foot shock in the latter. “We saw a very dramatic phenotype,” Bading said. “Probably the circuitry is not connecting in the right way.”

Loss of VEGF-D activity could also be involved in neurodegeneration, Bading speculated. “I would be very surprised if there are not pathological conditions where VEGF-D expression falls…which could then have impact on brain function,” he said. There is evidence of dendritic atrophy in aging and Alzheimer’s (see review by Dickstein et al., 2007). Other members of the VEGF family are involved in neurogenesis, neuroprotection, and learning and memory (Cao et al., 2004; Poesen et al., 2008; Le Bras et al., 2006; Licht et al., 2010). Certain VEGF-A alleles increase risk of amyotrophic lateral sclerosis due to reduced VEGF-A protein levels (Lambrechts et al., 2003; Lambrechts et al., 2008). However, Bading and colleagues did not find any evidence that VEGF members, other than VEGF-D, are involved in dendritic arborization.

While they are protective in nerves, VEGF proteins enhance angiogenesis, which can support tumor growth (Achen and Stacker, 2008; Stacker et al., 2001). Researchers are pursuing VEGF-D blockers as cancer treatments (Heath and Bicknell, 2009). Unfortunately, preventing VEGF-D activity in the nervous system could impair cognition. “If VEGF-D blockers get into the brain, it could be bad news,” Bading said.

Bading noted that there is an intriguing similarity between the protein’s neural and vascular roles: In both places, it promotes branching. The scientists have not yet worked out the full mechanism between VEGF-D signaling and dendritic arborization; VEGF-D appears to bind the type 3 VEGF receptor and activate the MAP kinase p38, but it is not clear if VEGF-D-mediated pathways toward angiogenesis and dendrite arborization are the same. La Spada suggested that a more detailed understanding of these mechanisms might help scientists design drugs that only target one or the other.—Amber Dance.

Reference:
Mauceri D, Freitag HE, Oliveira AM, Bengtson CP, Bading H. Nuclear calcium-VEGFD signaling controls maintenance of dendrite arborization necessary for memory formation. Neuron. 2011 Jul 14;71(1):117-30. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Nuclear calcium-VEGFD signaling controls maintenance of dendrite arborization necessary for memory formation.

Comment by:  Albert La Spada
Submitted 18 July 2011  |  Permalink Posted 18 July 2011

I find this work to be very compelling. A role for VEGF in motor neuron disease was suggested by studies done on ALS and by work that we have done on spinobulbar muscular atrophy. Hence, numerous independent studies have now shown that VEGF may be a neurotrophic factor and has neuroprotective properties. This most recent work from the Bading group confirms such findings, but goes further, as they were able to show that knockdown of VEGF-D in mice resulted in impaired memory formation in vivo. While there has been interest in the potential of VEGF as a neurotherapeutic, VEGF has angiogenic properties, raising concern that it could cause side effects. These researchers report that VEGF-R3 is the receptor that likely mediates the elaboration of dendritic arbors. If this is true, then future studies aimed at defining the downstream pathway by which VEGF-R3 activation yields dendritic arborization could identify targets for therapy development, since neuroprotective pathways might be distinct from angiogenic ones.

View all comments by Albert La Spada
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad